Author:
Ekenberg Luna Fabricius,Lindgren Line Markdanner,Pehrson Caroline
Abstract
This is a case report of a 44-year-old premenopausal woman who was admitted to hospital due to uncontrollable and life-threatening vaginal bleeding after starting rivaroxaban treatment for atrial fibrillation. She had a medical history with menorrhagia due to an intrauterine fibroma. She did not respond sufficiently to factor X supplement or other non-surgical medical interventions. The bleeding subsided after bilateral embolization of aa. uterinae.
Publisher
Danish Medical Association
Reference5 articles.
1. Speed V, Patel JP, Arya R. Bleeding issues in women prescribed anticoagulation. Thromb Update. 2021;5:100068. https://doi.org/10.1016/j.tru.2021.100068
2. Beyer-Westendorf J, Michalski F, Tittl L et al. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Lancet Haematol. 2016;3(10):e480-e488. https://doi.org/10.1016/S2352-3026(16)30111-9
3. Eworuke E, Hou L, Zhang R et al. Risk of severe abnormal uterine bleeding associated with rivaroxaban compared with apixaban, dabigatran and warfarin. Drug Saf. 2021;44(7):753-763. https://doi.org/10.1007/s40264-021-01072-0
4. Hellfritzsch M, Hvas AM, Dueholm M et al. Menoragi under antikoagulansbehandling. Ugeskr Læger. 2020;182:V08200614.
5. Dansk Cardiologisk Selskab. 14. Antikoagulationsbehandling. Dansk Cardiologisk Selskab, 2023. https://nbv.cardio.dk/ak (4. feb 2024)